Canaccord initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $19 price target The firm believes now is the time to buy Wave Life shares. The company’s “robust” pipeline includes potential milestone and future royalty payments associated with WVE-006 for alpha-1 antitrypsin deficiency, a large obesity opportunity with WVE-007, a potential first commercial approval of WVE-N531 for Exon 53 in the next year, and WVE-003 for Huntington disease, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences initiated with a Buy at Canaccord
- Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy’ Stocks
- Wave Life Sciences Poised for Growth: Buy Rating Affirmed Amid Upcoming Catalysts
- Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges
- Wave Life Sciences Advances RNA Medicine Pipeline